Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers

Nature Communications

Volumn 7, Issue , 2016, Pages

  Miller, Christopher A ^a   Gindin, Yevgeniy ^a   Lu, Charles ^a   Griffith, Obi L ^a,b   Griffith, Malachi ^a,b   Shen, Dong ^a   Hoog, Jeremy ^a   Li, Tiandao ^a   Larson, David E ^a   Watson, Mark ^a   Davies, Sherri R ^a   Hunt, Kelly ^c   Suman, Vera J ^d   Snider, Jacqueline ^a   Walsh, Thomas ^a   Colditz, Graham A ^a,b   Deschryver, Katherine ^a   Wilson, Richard K ^a,b   Mardis, Elaine R ^a,b   Ellis, Matthew J ^a,e  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Washington University in St Louis School of Medicine   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d MAYO CLINIC   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARID1A PROTEIN; ARID2 PROTEIN; AROMATASE; AROMATASE INHIBITOR; B RAF KINASE; BIRC6 PROTEIN; CCND1 PROTEIN; ESTROGEN RECEPTOR ALPHA; FIZZY RELATED PROTEIN; HISTONE DEMETHYLASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; ESTROGEN RECEPTOR; TUMOR MARKER;

CANCER; DISEASE TREATMENT; ENZYME ACTIVITY; ESTROGENIC COMPOUND; GENETIC ANALYSIS; GENOMICS; HETEROGENEITY; INHIBITION; INHIBITOR; MUTATION; RNA; TUMOR;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER SURGERY; CLINICAL ARTICLE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FRAMESHIFT MUTATION; GENETIC VARIABILITY; GENOME; GENOMICS; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDEL MUTATION; LIGAND BINDING; LIMIT OF DETECTION; MIDDLE AGED; MISSENSE MUTATION; MOLECULAR CLONING; RNA SEQUENCE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE VARIANT; SOMATIC MUTATION; VERY ELDERLY; WHOLE GENOME SEQUENCING; ALLELE; BREAST TUMOR; CELL CLONE; GENETICS; HUMAN GENOME; METABOLISM; MUTATION; TUMOR CELL LINE;

ALLELES; AROMATASE; AROMATASE INHIBITORS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL LINE, TUMOR; CLONE CELLS; FEMALE; GENOME, HUMAN; HUMANS; MUTATION; RECEPTORS, ESTROGEN;

EID: 84981725439     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12498     Document Type: Article

References (34)

1. Ma, C. X., Reinert, T., Chmielewska, I. & Ellis, M. J. Mechanisms of aromatase inhibitor resistance. Nat. Rev. Cancer 15, 261-275 (2015)
2. Miller, W. R. et al. Predicting response and resistance to endocrine therapy: profiling patients on aromatase inhibitors. Cancer 112, 689-694 (2008)
3. Ma, C. X., Sanchez, C. G. & Ellis, M. J. Predicting endocrine therapy responsiveness in breast cancer. Oncology (Williston Park) 23, 133-142 (2009)
4. Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23-28 (1976)
5. Welch, J. S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264-278 (2012)
6. Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994-1007 (2012)
7. Zhang, J. et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346, 256-259 (2014)
8. de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256 (2014)
9. Gerlinger, M. & Swanton, C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br. J. Cancer 103, 1139-1143 (2010)
10. Yap, T. A., Gerlinger, M., Futreal, P. A., Pusztai, L. & Swanton, C. Intratumor heterogeneity: seeing the wood for the trees. Sci. Transl. Med. 4, 127ps10 (2012)
11. Turke, A. B. et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77-88 (2010)
12. Su, K.-Y. et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 30, 433-440 (2012)
13. Juric, D. et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Ka inhibitor. Nature 518, 240-244 (2015)
14. Hartman, M. et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J. Clin. Oncol. 25, 4210-4216 (2007)
15. Wahner-Roedler, D. L., Reynolds, C. A. & Boughey, J. C. Collision tumors with synchronous presentation of breast carcinoma and lymphoproliferative disorders in the axillary nodes of patients with newly diagnosed breast cancer: a case series. Clin. Breast Cancer 11, 61-66 (2011)
16. Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399 (2012)
17. Li, S. et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 4, 1116-1130 (2013)
18. Miller, W. R. et al. Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet. Genomics 17, 813-826 (2007)
19. Mackay, A. et al. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res. 9, R37 (2007)
20. Ellis, M. J. et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486, 353-360 (2012)
21. Mardis, E. R. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058-1066 (2009)
22. Miller, C. A. et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput. Biol. 10, e1003665 (2014)
23. Gururaj, A. E., Holm, C., Landberg, G. & Kumar, R. Breast cancer-amplified sequence 3, a target of metastasis-associated protein 1, contributes to tamoxifen resistance in premenopausal patients with breast cancer. Cell Cycle 5, 1407-1410 (2006)
24. Toy, W. et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45, 1439-1445 (2013)
25. Robinson, D. R. et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45, 1446-1451 (2013)
26. Ellis, M. J. et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J. Natl Cancer Inst. 100, 1380-1388 (2008)
27. Foukakis, T., Astrom, G., Lindstrom, L., Hatschek, T. & Bergh, J. When to order a biopsy to characterise a metastatic relapse in breast cancer. Ann. Oncol. 23(Suppl 10): x349-x353 (2012)
28. Bose, R. et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 3, 224-237 (2013)
29. Ellis, M. J. Functional analysis of the breast cancer genome. J. Clin. Oncol. 24, 1649-1650 (2006)
30. Ellis, M. J. et al. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res. Treat. 119, 379-390 (2010)
31. Ellis, M. J. et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J. Clin. Oncol. 29, 2342-2349 (2011)
32. Olson, J. A. et al. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J. Am. Coll. Surg. 208, 906-914 (2009), discussion 915-916
33. Griffith, M. et al. Genome modeling system: a knowledge management platform for genomics. PLoS Comput. Biol. 11, e1004274 (2015)
34. Zhang, J. et al. INTEGRATE: gene fusion discovery using whole genome and transcriptome data. Genome Res. 26, 108-118 (2016)